Skip to main content

Advertisement

SpringerLink
Log in

Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: Correlation with the effect of a single administration of octreotide on serum TSH levels

  • Original Article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Few data are available on the visualization of somatostatin receptors in vivo in patients with thyrotropin (TSH)-secreting adenoma. We studied five patients with TSH-secreting adenomas using single-photon emission tomography (SPET) after administration of indium-111 pentetreotide. The intensity of111In-pentetreotide uptake by the tumours was correlated with the degree of TSH suppression after a single administration of 100 μg octreotide s.c. Five patients (three women and two men) aged 27–46 years were investigated. Except for one patient with acromegaly, all had pure TSH-secreting inmours. One patient was previously untreated, while two had received octreotide, one antithyroid drugs, and one radioiodine. In all patients SPET demonstrated increased uptake of111In-pentetreotide by the pituitary adenoma. The target to non-target ratio (T/nT) of111In-pentetreotide uptake was higher than 10 in three patients. Administration of 100 μg octreotide s.c. caused a significant reduction in TSH levels from 4.8±1.4 mU/l to a nadir of 3.1±1.1 mU/l after 6 h (P<0.001 by ANOVA). Suppression of TSH secretion ranged from 30% to 60% of the baseline value. The T/nT ratio showed a trend toward a direct relationship with the degree of TSH inhibition after acute octreotide administration (r=0.67;P=NS). Our study showed that111In-pentetreotide scan visualized somatostatin receptors in all five of the patients with TSH-secreting pituitary adenomas, confirming the frequent presence of somatostatin receptors in these rare tumours, even though the correlation with the TSH inhibition after a single administration of octreotide did not reach significance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Faglia G, Beck-Peccoz P, Piscitelli G, Medri G. Inappropriate secretion of thyrotropin by the pituitary. Horm Res 1987; 26: 79–99.

    PubMed  Google Scholar 

  2. Beck-Peccoz P, Persani L. Thyrotropin (TSH)-secreting pituitary tumors: endocrinology, clinical aspects and treatment. In: Landolt AM, Vance ML, Reilly PL, eds.Pituitary adenomas: biology, diagnosis and treatment. London: Churchill Livingstone; 1996: 139–155.

    Google Scholar 

  3. Gesundheit N, Petrick PA, Nissim M, et al. Thyrotropin-secreting pituitary adenomas: clinical and biochemical heterogeneity. Case reports and follow-up of nine patients.Ann Intern Med 1989; 111: 827–835.

    PubMed  Google Scholar 

  4. McCutcheon IE, Weintraub BD, Oldfield EH. Surgical treatment of thyrotropin-secreting pituitary adenomas.J Neurosurg 1990; 73: 674–683.

    PubMed  Google Scholar 

  5. Smallridge RC. Thyrotropin-secreting pituitary tumors.Endocrinol Metab Clin North Am 1987; 16: 765–791.

    PubMed  Google Scholar 

  6. Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid stimulating secreting pituitary adenomas. A follow-up of 52 patients.Ann Intern Med 1993; 119: 236–240.

    PubMed  Google Scholar 

  7. Connel S, McCruden DC, Davies DL, Alexander W. Bromocriptine for inappropriate thyrotropin secretion.Ann Intern Med 1982; 96: 251–252.

    PubMed  Google Scholar 

  8. Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue.N Engl J Med 1987; 317: 12–17.

    PubMed  Google Scholar 

  9. Gancel A, Vuillermet P, Legrand A, Cams F, Thomas F, Kuhn JM. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.Clin Endocrinol (Oxf) 1994; 40: 421–428.

    Google Scholar 

  10. Beck-Peccoz P, Mariotti S, Guillausseau J, et al. Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995.J Clin Endocrinol Metab 1989; 68: 208–214.

    PubMed  Google Scholar 

  11. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors.N Engl J Med 1990; 323: 1246–1249.

    PubMed  Google Scholar 

  12. Krenning EP, Bakker WH, Kooij PPM, et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]-octreotide in man: metabolism, dosimetry and comparison with [123I-Tyr3]-octreotide.J Nucl Med 1992; 33: 652–658.

    PubMed  Google Scholar 

  13. Lamberts SWJ, Hofland LJ, van Koetsveld PM, et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization and therapy.J Clin Endocrinol Metab 1990; 71: 566–574.

    PubMed  Google Scholar 

  14. Faglia G, Bazzoni N, Spada A, et al. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204-090).J Clin Endocrinol Metab 1991; 73: 850–856.

    PubMed  Google Scholar 

  15. Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas.J Clin Endocrinol Metab 1996; 81: 3084–3090.

    PubMed  Google Scholar 

  16. de Herder WW, Krenning EP, Malchoff CD, et al. Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion.Am J Med 1994; 96: 305–312.

    PubMed  Google Scholar 

  17. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the treatment of tumors.Endocr Rev 1991; 12: 450–482.

    PubMed  Google Scholar 

  18. Lamberts SWJ, Krenning EP, Bakker WH, Breeman WAP, Kooij PPM, Reubi JC. Somatostatin receptor imaging in the diagnosis of pituitary and parasellar tumours. In: Melmed S, Robbins RJ, eds. Molecular and clinical advances in pituitary disorders. Boston: Blackwell Scientific; 1990: 85–292.

    Google Scholar 

  19. Verhoeff NPLG, Bemelman FJ, Wiersinga WM, van Royen EA. Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma.Eur J Nucl Med 1993; 20: 555–561.

    PubMed  Google Scholar 

  20. Pierantoni MC, Gasperi M, Molea N, et al. Use of111In-pentetreotide scan in the diagnosis and follow up of pituitary adenomas [abstract].J Endocrinol Invest 1995 Suppl 5: 58.

    Google Scholar 

  21. Bertherat J, Brue T, Enjalbert A, et al. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.J Clin Endocrinol Metab 1992; 75: 540–546.

    PubMed  Google Scholar 

  22. Reubi JC, Landolt AM. High density of somatostatin receptors in pituitary tumors from acromegalic patients.J Clin Endocrinol Metab 1984; 59: 1148–1151.

    PubMed  Google Scholar 

  23. Colao A, Lastoria S, Ferone D, et al. Pituitary imaging by labelled indium-111 octreotide (In-111 OCT): a reliable tool to differentiate patients with GH-secreting adenomas responders to chronic treatment [abstract].J Endocrinol Invest 1994; 17 Suppl 2: 42.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, IRCCS San Raffaele, via Olgetinna 60, I-20132, Milano, Italy

    M. Losa, P. Mortini, S. Acerno, E. Giugni & M. Giovanelli

  2. INB-CNR Department of Nuclear Medicine, IRCCS San Raffaele, University of Milan, Italy

    P. Magnani, C. Songini & F. Fazio

  3. Centro Auxologico Italiano IRCCS, University of Milan, Italy

    L. Persani

  4. Institute of Endocrine Sciences, Istituto Clinico Humanitas, University of Milan, Italy

    P. Beck-Peccoz

Authors
  1. M. Losa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Magnani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Mortini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Persani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Acerno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Giugni
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Songini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Fazio
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. Beck-Peccoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Giovanelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Losa, M., Magnani, P., Mortini, P. et al. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: Correlation with the effect of a single administration of octreotide on serum TSH levels. Eur J Nucl Med 24, 728–731 (1997). https://doi.org/10.1007/BF00879659

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00879659

Key words

Search

Navigation